Mark J. Dearman

Partner at Robbins Geller Rudman & Dowd LLP

Mark Dearman is a partner in Robbins Geller Rudman & Dowd LLP’s Boca Raton office, where his practice focuses on consumer fraud, securities fraud, mass torts, antitrust, and whistleblower litigation.

Mark was a member of the faculty of the inaugural Mass Tort MDL Certificate Program at the Bolch Judicial Institute of Duke Law School (March 2019). Before joining Robbins Geller, Mark spent several years defending Fortune 500 companies in all aspects of litigation, with an emphasis in complex commercial litigation, consumer claims, and mass torts (products liability and personal injury). He went on to found the firm of Dearman & Gerson, where he continued to defend many publicly traded corporations for over 12 years. Over  the last 30 years of practice, Mark has obtained extensive jury trial experience on the plaintiffs’ side, protecting the rights of consumers throughout the United States.

Notable Cases

  • Mark, along with other Robbins Geller attorneys, is currently leading the effort on behalf of cities and counties around the country in In re National Prescription Opiate Litigation, No. 1:17-md-02804-DAP (N.D. Ohio).
  • He was appointed to the Plaintiffs’ Steering Committee in In re Zantac (Ranitidine) Products Liability Litigation, No. 9:20-md-02924-RLR (S.D. Fla.), and as Chair of the Plaintiffs’ Executive Committee in In re Apple Inc. Device Performance Litigation, No. 5:18-md-02827-EJD (N.D. Cal.), Mark, along with co-counsel, obtained a $310 million settlement.
  • In re Facebook Biometric Information Privacy Litigation, No. 3:15-cv-03747-JD (N.D. Cal.) ($650 million recovery in a  class action concerning Facebook’s alleged privacy violations through its collection of user’s biometric identifiers without informed consent);
  •  In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices & Antitrust Litigation, No. 2:17-md-02785-DDC-TJJ (D. Kan.) ($609 million total recovery achieved weeks prior to trial in certified class action alleging antitrust claims involving the illegal reverse payment settlement to delay the generic EpiPen);

Education

  • Nova Southeastern University, J.D., 1993
  • University of Florida, B.A., 1990

Honors

  • AV rating by Martindale-Hubbell
  • Leading Plaintiff Financial Lawyer, Lawdragon, 2020-2023
  • Leading Plaintiff Consumer Lawyer, Lawdragon, 2022-2023
  • Leading Lawyer in America, Lawdragon, 2023

Associations

  • Faculty, Mass Torts MDL Certificate Program, Bolch Judicial Institute of Duke Law School